Back to top
more

HealthEquity (HQY)

(Real Time Quote from BATS)

$92.98 USD

92.98
66,625

+1.14 (1.24%)

Updated Aug 8, 2025 10:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (97 out of 244)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

BD (BDX) to Expand Base in Pharmacy Automation With New Buyout

by Zacks Equity Research

BD's (BDX) buyout of Parata Systems is expected to advance its 2025 strategy to accelerate innovation in smart, connected care and enabling new care settings.

Zacks Equity Research

HealthEquity (HQY) Q1 Earnings Lag Estimates, FY23 View Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust segmental revenues, in the first quarter of fiscal 2023.

Zacks Equity Research

Here's Why You Should Hold on to Avanos (AVNS) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

Zacks Equity Research

HealthEquity (HQY) Q1 Earnings Miss Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of -3.57% and 1.46%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Assure Holdings Corp. (IONM) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Assure Holdings Corp. (IONM) delivered earnings and revenue surprises of -216.67% and 27.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

InnovAge Holding Corp. (INNV) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -300% and 5.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Viatris (VTRS) Q1 Earnings Beat Estimates

by Zacks Equity Research

Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HealthEquity (HQY) Q4 Earnings Lag Estimates, Margins Down

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, along with recording robust Custodial and Interchange revenues, in the fourth quarter of fiscal 2022.

Zacks Equity Research

HealthEquity (HQY) Q4 Earnings Miss Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of -4.76% and 2.02%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: HealthEquity (HQY) Q4 Earnings Expected to Decline

by Zacks Equity Research

HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

DermTech, Inc. (DMTK) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -20.55% and 5.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of -10% and 1.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ModivCare (MODV) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

ModivCare (MODV) delivered earnings and revenue surprises of 28.66% and 4.12%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Abbott (ABT) Gets FDA Approval for CardioMEMS HF System

by Zacks Equity Research

Abbott's (ABT) CardioMEMS HF System will enable physicians to monitor for early warning signs of worsening heart failure before it progresses to a later stage.

Zacks Equity Research

Here's Why You Should Hold on to STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on its better-than-expected earnings in the fiscal third quarter and the ongoing integration of the Cantel Medical business.

Zacks Equity Research

Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now

by Zacks Equity Research

Robust domestic and international performances by the CAG arm are driving IDEXX's (IDXX) fourth-quarter top line.

Zacks Equity Research

Tandem Diabetes (TNDM) to Offer Insulin Delivery With Smartphone

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:connect is the first-ever app on both iOS and Android operating systems to receive FDA clearance for insulin delivery from a personal smartphone.

Zacks Equity Research

OPKO's (OPK) NGENLA to Offer GHD Treatment in European Union

by Zacks Equity Research

OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.

Zacks Equity Research

Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.

Zacks Equity Research

HealthEquity (HQY) Up 10.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

New Strong Sell Stocks for December 21st

by Zacks Equity Research

BLBD, CBRL, HQY, LE and PHX have been added to the Zacks Rank #5 (Strong Sell) List on December 21, 2021.

Zacks Equity Research

New Strong Sell Stocks for December 10th

by Zacks Equity Research

AVAV, HQY, MESA, SWK, and CGNX have been added to the Zacks Rank #5 (Strong Sell) List on December 10, 2021.

Zacks Equity Research

Here's Why You Should Hold on to Align Technology (ALGN) Now

by Zacks Equity Research

Investors are optimistic about Align Technology's (ALGN) better-than-expected results and growing uptake of iTero scanners in the third quarter of fiscal 2021.

Zacks Equity Research

Medtronic (MDT) Gets Health Canada License for Hugo RAS System

by Zacks Equity Research

The receipt of the Health Canada license for Medtronic's (MDT) Hugo RAS System is likely to enhance accessibility to robotic-assisted surgery in Canada.